Deutsch Liat, Cloutier Anabelle, Lal Simon
The Department of Gastroenterology and Liver diseases, Tel-Aviv Sourasky Medical Centre and Sackler Faculty of Medicine, Tel-Aviv University, Israel.
Intestinal Failure Unit, Salford Royal NHS Foundation Trust, Salford.
Curr Opin Gastroenterol. 2020 May;36(3):223-229. doi: 10.1097/MOG.0000000000000631.
To summarize changes and recent advances in therapies for chronic intestinal failure (CIF).
In the last few years, the management of CIF has significantly improved through better prevention and treatment of catheter-related bloodstream infections (CRBSIs) and intestinal failure-associated liver disease (IFALD), as well as improved enteral autonomy by using small bowel growth factors in selected patients. This may have been reflected by a recent reduction in small bowel transplantations.
Although CIF management has become more established and effective, the long-term implications of parenteral nutrition still place substantial burden on patients such that further work is required to improve patients' quality of life as well as continued efforts to reduce complications relating to CIF management.
总结慢性肠衰竭(CIF)治疗方法的变化和近期进展。
在过去几年中,通过更好地预防和治疗导管相关血流感染(CRBSI)和肠衰竭相关肝病(IFALD),以及在特定患者中使用小肠生长因子提高肠内自主性,CIF的管理有了显著改善。这可能反映在近期小肠移植数量的减少上。
尽管CIF的管理已变得更加成熟和有效,但肠外营养的长期影响仍然给患者带来沉重负担,因此需要进一步努力改善患者生活质量,并持续致力于减少与CIF管理相关的并发症。